Drug
Fludarabine phosphate clinical trials
Also written Fludara, 2-F-ara-AMP, Oforta and BAY86-4864.
A product of Fludarabine; its studies count on that page too.
- studies test it
- 259
- open now
- 15
- in phase 3
- 12
- first study started
- 1995
Keep track of what changes. Save the fludarabine phosphate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
- 2-F-ara-AMP
- 103
Studies by the year they started
257 studies that test it; most in 2005 (22)
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1996 | 1 |
| 1997 | 2 |
| 1998 | 10 |
| 1999 | 13 |
| 2000 | 12 |
| 2001 | 15 |
| 2002 | 17 |
| 2003 | 17 |
| 2004 | 19 |
| 2005 | 22 |
| 2006 | 16 |
| 2007 | 13 |
| 2008 | 9 |
| 2009 | 8 |
| 2010 | 10 |
| 2011 | 4 |
| 2012 | 10 |
| 2013 | 5 |
| 2014 | 9 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 89
- Phase 2
- 180
- Phase 3
- 12
- Phase 4
- 1
- No phase
- 15
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 250
Fred Hutchinson Cancer Center (60) · M.D. Anderson Cancer Center (22) · National Cancer Institute (NCI) (20) · Masonic Cancer Center, University of Minnesota (14) · Alliance for Clinical Trials in Oncology (12) · City of Hope Medical Center (9) · Roswell Park Cancer Institute (8) · University of California, San Francisco (8)
Often tested with
Tested in the same studies.
Cyclophosphamide (108) · Busulfan (49) · Mycophenolic Acid (47) · Melphalan (37) · Tacrolimus (36) · Cyclosporine (32) · Rituximab (31) · Antilymphocyte Serum (22)
Studies
Open first, then newest update. How each study uses fludarabine phosphate is read from its arms, and is right about nine times in ten.
Testing it · 259
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as fludarabine phosphate
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT07582172Written as Fludarabine Phosphate
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT00801489Written as Fludarabine Phosphate
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06066424Written as Fludarabine phosphate
- Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1Roswell Park Cancer InstituteNCT06871410Written as Fludarabine Phosphate
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant DisordersRecruitingPhase 2Fred Hutchinson Cancer CenterNCT03980769Written as Fludarabine Phosphate
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06383572Written as Fludarabine phosphate
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT05092451Written as Fludarabine phosphate
- Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)RecruitingPhase 2University of Illinois at ChicagoNCT06802315Written as Fludarabine (Fludara)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute LeukemiaRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT03128034Written as Fludarabine Phosphate
- Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 1He HuangNCT06809712Written as Fludarabine (Fludara)
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingPhase 3Martin SchrappeNCT03643276Written as Fludarabine Phosphate
- Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 1He HuangNCT06809699Written as Fludarabine (Fludara)
- CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular CarcinomaNot yet recruitingPhase 1/2Chinese PLA General HospitalNCT06641453Written as Fludarabine Phosphate for Injection
- AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple SclerosisRecruitingPhase 1St. Petersburg State Pavlov Medical UniversityNCT05832515Written as Fludarabine Phosphate for Injection
- Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaActive, not recruitingPhase 2City of Hope Medical CenterNCT04262843Written as Fludarabine Phosphate
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02250937Written as Fludarabine Phosphate
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingPhase 1City of Hope Medical CenterNCT02153580Written as Fludarabine Phosphate
- Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02629809Written as Fludarabine Phosphate
- Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST TrialSuspendedPhase 1National Cancer Institute (NCI)NCT04539366Written as Fludarabine Phosphate
See all 259 studies that test fludarabine phosphate →
Given in every arm · 114 — fludarabine phosphate is usual care beside what is tested
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06434363Written as Fludarabine phosphate
- Emapalumab Prevention of CAR-T Cell Associated ToxicitiesRecruitingPhase 2Marcela V. Maus, M.D.,Ph.D.NCT06550141Written as Fludarabine Phosphate
- Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R MyelomaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06066359Written as Fludarabine phosphate
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2St. Jude Children's Research HospitalNCT05955261Written as Fludarabine Phosphate
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06345495Written as Fludarabine phosphate
- A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06043323Written as Fludarabine phosphate
- Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological MalignancesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT05110742Written as Fludarabine Phosphate
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingPhase 2/3M.D. Anderson Cancer CenterNCT04708054Written as Fludarabine Phosphate
- Personalized NK Cell Therapy in CBTRecruitingPhase 2M.D. Anderson Cancer CenterNCT02727803Written as Fludarabine Phosphate
- Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1RecruitingPhase 1M.D. Anderson Cancer CenterNCT06083883Written as Fludarabine phosphate
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06013423Written as Fludarabine Phosphate
- Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1University of California, DavisNCT05052528Written as Fludarabine Phosphate
- Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)Not yet recruitingPhase 2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07603557Written as Fludarabine Phosphate
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT03670966Written as Fludarabine Phosphate
- Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesRecruitingPhase 1Sumithira VasuNCT05418088Written as Fludarabine Phosphate
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)RecruitingPhase 1/2Beijing BiotechNCT07486089Written as Lymphodepleting chemotherapy
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingPhase 1Anusha KalbasiNCT04119024Written as Fludarabine Phosphate
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic MelanomaRecruitingPhase 1Inge Marie SvaneNCT06204991Written as Fludarabine Phosphate
- Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02RecruitingPhase 1Celyad Oncology SANCT04167696Written as Fludara
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaCompletedPhase 1City of Hope Medical CenterNCT01163357Written as fludarabine phosphate
Showing 20 of 114.
As the comparator · 3 — what is tested is compared with fludarabine phosphate
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02048813Written as Fludarabine Phosphate
- Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedPhase 3Hackensack Meridian HealthNCT01366612Written as Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
- Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) PatientsCompletedPhase 3Genzyme, a Sanofi CompanyNCT00086580Written as fludarabine phosphate
Codes
What other systems call fludarabine phosphate · ClinicalTrials.gg INT003160
- MeSH (NLM) C042382fludarabine phosphateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1X9VK9O1SCFLUDARABINE PHOSPHATEConfirmed FDA, NLM, Wikidata
- RxNorm 25102Confirmed FDA, Wikidata
- Wikidata Q185916fludarabine phosphateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1102Fludarabine PhosphateOne source FDA
- DrugBank DB01073One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C042382 | fludarabine phosphate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1X9VK9O1SC | FLUDARABINE PHOSPHATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 25102 | — | Confirmed FDA, Wikidata |
| Wikidata | Q185916 | fludarabine phosphate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1102 | Fludarabine Phosphate | One source FDA |
| DrugBank | DB01073 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.